Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

ICR study predicts response to radium-233 treatment in prostate cancer bone metastases

The findings could help determine which patients would benefit from the treatment

- PMLiVE

Breaking barriers: strategies for expanding patient access to cell and gene therapies

How innovation can help to overcome the hurdles that prevent access to cell and gene therapies

- PMLiVE

AstraZeneca to acquire cell therapy specialist Gracell in deal worth up to $1.2bn

The transaction includes a clinical-stage candidate being evaluated as a treatment for multiple myeloma

- PMLiVE

World Health Organization adds second malaria vaccine to prequalification list

The addition is expected to result in sufficient malaria vaccine supply for children

- PMLiVE

T is for trouble

Evolution trumps transformation

- PMLiVE

GSK gains rights to Hansoh’s ADC candidate in deal worth more than $1.7bn

HS-20093 is being developed for a range of solid tumour types, including lung cancer

- PMLiVE

Nanoparticle-delivered RNA could offer potential therapy for neuroinflammation

The study demonstrated a new way to deliver RNA to the brain's immune cells

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

EMA and HMAs publish workplan to guide use of AI in medicines regulation

The document aims to maximise the benefits and mitigate the risks of AI in medicine

- PMLiVE

Reaching the full potential of gene therapy through increased genetic testing

How early diagnosis and advances in gene-focused treatments could transform the lives of patients with rare cardiovascular disease

KVA Christmas Present Appeal 2023

KVA drive Christmas present appeal for children’s hospital

Every year, KVA organise a Christmas present appeal for Stoke Mandeville Hospital, Buckinghamshire and this year their team felt especially generous with a huge collection of Christmas presents.

KVA

- PMLiVE

Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links